In line with the updated advice from WHO, neither the PaedF working party nor the EDQM recommend the use of the below listed drugs outside their authorised indications for experimental treatment of COVID-19. The prescriber remains responsible to make an individual assessment of risks and benefits for each patient. The European Medicines Agency also advises to only use the below listed drugs for their authorised indications or within clinical trials or emergency use programmes in hospitalised patients.